KEGG   DRUG: Trastuzumab deruxtecan
Entry
D11529                      Drug                                   
Name
Trastuzumab deruxtecan (USAN/INN);
Trastuzumab deruxtecan (genetical recombination) (JAN);
Fam-trastuzumab deruxtecan-nxki;
Enhertu (TN)
Product
ENHERTU (Daiichi Sankyo)
Formula
C6460H9972N1724O2014S44. (C52H57FN9O13)8
Exact mass
153607.1079
Mol weight
153702.05
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03158  HER2 inhibitor
Remark
Therapeutic category: 4291
ATC code: L01FD04
Product: D11529<JP/US>
Efficacy
Antineoplastic
  Disease
Breast cancer (HER2 positive) [DS:H00031]
Breast cancer (HER2 low) [DS:H00031]
Non-small cell lung cancer (HER2 mutant) [DS:H00014]
Gastric cancer (HER2 positive) [DS:H00018]
Solid tumor (HER2 positive IHC 3+) [DS:H02421]
  Type
Antibody-drug conjugate
Target
ERBB2* (HER2, CD340) [HSA_VAR:2064v1] [HSA:2064] [KO:K05083]
TOP1 [HSA:7150] [KO:K03163]
  Pathway
hsa01521  EGFR tyrosine kinase inhibitor resistance
hsa04012  ErbB signaling pathway
hsa05200  Pathways in cancer
  Network
nt06266  Non-small cell lung cancer
nt06270  Breast cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
     L01FD04 Trastuzumab deruxtecan
      D11529  Trastuzumab deruxtecan (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Anti-HER2 Antibodies
    Fam-Trastuzumab Deruxtecan
     D11529  Trastuzumab deruxtecan (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D11529  Trastuzumab deruxtecan (USAN/INN); Trastuzumab deruxtecan (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     D11529  Trastuzumab deruxtecan
Drug classes [BR:br08332]
 Antineoplastic
  DG03158  HER2 inhibitor
   D11529  Trastuzumab deruxtecan
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
     D11529  Trastuzumab deruxtecan (USAN/INN) <JP/US>
 Enzymes
  Isomerases (EC5)
   DNA topoisomerase
    TOP1
     D11529  Trastuzumab deruxtecan (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11529
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11529
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11529
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11529
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D11529
Other DBs
CAS: 1826843-81-5
PubChem: 384585505
LinkDB

» Japanese version   » Back

KEGG   DRUG: Amivantamab
Entry
D11894                      Drug                                   
Name
Amivantamab (USAN/INN);
Amivantamab (genetical recombination) (JAN);
Amivantamab-vmjw;
Rybrevant (TN)
Product
RYBREVANT (Janssen Biotech)
Formula
C6472H10014N1730O2023S46
Exact mass
145810.1055
Mol weight
145900.22
Sequence
(A chain)
QVQLVESGGG VVQPGRSLRL SCAASGFTFS TYGMHWVRQA PGKGLEWVAV IWDDGSYKYY
GDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDG ITMVRGVMKD YFDYWGQGTL
VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KRVEPKSCDK THTCPPCPAP
ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFLLYSKLTV
DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK
(B chain)
QVQLVQSGAE VKKPGASVKV SCETSGYTFT SYGISWVRQA PGHGLEWMGW ISAYNGYTNY
AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDL RGTNYFDYWG QGTLVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ
QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
(C chain)
AIQLTQSPSS LSASVGDRVT ITCRASQDIS SALVWYQQKP GKAPKLLIYD ASSLESGVPS
RFSGSESGTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(D chain)
DIQMTQSPSS VSASVGDRVT ITCRASQGIS NWLAWFQHKP GKAPKLLIYA ASSLLSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ ANSFPITFGQ GTRLEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: A22-A96, A152-A208, A228-C214, A234-B228, A237-B231, A269-A329, A375-A433, B22-B96, B146-B202, B222-D214, B263-B323, B369-B427, C23-C88, C134-C194, D23-D88, D134-D194)
  Type
Peptide
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03162  EGFR inhibitor
Remark
Therapeutic category: 4291
ATC code: L01FX18
Product: D11894<JP/US>
Efficacy
Antineoplastic
  Disease
Non-small cell lung cancer (EGFR exon 20 insertion) [DS:H00014]
  Type
Bispecific antibody
Target
EGFR* [HSA_VAR:1956v2] [HSA:1956] [KO:K04361]
MET [HSA:4233] [KO:K05099]
  Pathway
hsa04010  MAPK signaling pathway
hsa04014  Ras signaling pathway
hsa04015  Rap1 signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa04510  Focal adhesion
hsa04520  Adherens junction
hsa05200  Pathways in cancer
hsa05223  Non-small cell lung cancer
  Network
nt06266  Non-small cell lung cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX18 Amivantamab
      D11894  Amivantamab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Anti-EGFR Antibodies
    Amivantamab
     D11894  Amivantamab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D11894  Amivantamab (USAN/INN); Amivantamab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03162  EGFR inhibitor
     D11894  Amivantamab
Drug classes [BR:br08332]
 Antineoplastic
  DG03162  EGFR inhibitor
   D11894  Amivantamab
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    EGFR* [HSA_VAR:1956v2]
     D11894  Amivantamab (USAN/INN) <JP/US>
   MET family
    MET
     D11894  Amivantamab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11894
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11894
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11894
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D11894
Other DBs
CAS: 2171511-58-1
PubChem: 497620307
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system